CGRP-Blocking Drugs: A New Class of Migraine Treatments
Seven CGRP antagonists in development, with three already FDA-approved, show strong efficacy and safety for migraine prevention and treatment.
Quick Facts
What This Study Found
Three FDA-approved CGRP antagonists and four more in clinical development demonstrate consistent efficacy in reducing migraine attacks with favorable safety profiles.
Key Numbers
7 CGRP antagonists; 3 approved; positive Phase 3 data; fewer side effects than traditional preventives
How They Did This
Review of phase 3 clinical trial data for seven CGRP antagonists, evaluating efficacy and safety outcomes.
Why This Research Matters
Migraine affects millions and current preventive treatments often fail or cause unacceptable side effects. CGRP antagonists offer a targeted, mechanism-based approach with better tolerability.
The Bigger Picture
CGRP antagonists represent the first migraine-specific preventive medications, marking a paradigm shift from repurposed drugs to targeted therapies based on migraine neurobiology.
What This Study Doesn't Tell Us
Review without meta-analysis. Long-term safety data beyond clinical trial durations are still accumulating.
Questions This Raises
- ?How do CGRP antagonists compare head-to-head against each other?
- ?What are the long-term safety implications of chronic CGRP blockade?
- ?Which patients benefit most from CGRP-targeted therapies versus existing preventives?
Trust & Context
- Key Stat:
- 3 approved FDA-approved CGRP antagonists for migraine prevention, with 4 more in development
- Evidence Grade:
- Review of phase 3 clinical trial data providing strong evidence for CGRP antagonist efficacy and safety.
- Study Age:
- Published in 2020. Since then, additional CGRP antagonists have received approval and more long-term data have become available.
- Original Title:
- Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.
- Published In:
- Journal of pain & palliative care pharmacotherapy, 34(1), 22-31 (2020)
- Database ID:
- RPEP-04850
Evidence Hierarchy
Frequently Asked Questions
What are CGRP antagonists and how do they prevent migraines?
CGRP antagonists block calcitonin gene-related peptide, a neuropeptide that plays a central role in triggering migraines. By blocking CGRP or its receptor, these drugs prevent the cascade of inflammation and pain signaling that causes migraine attacks.
Are CGRP antagonists better than older migraine drugs?
They offer a targeted approach with generally fewer side effects than repurposed medications like blood pressure drugs or antidepressants. They are particularly useful for patients who haven't responded to or couldn't tolerate existing preventive treatments.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04850APA
Henson, Brianna; Hollingsworth, Hanna; Nevois, Erika; Herndon, Chris. (2020). Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.. Journal of pain & palliative care pharmacotherapy, 34(1), 22-31. https://doi.org/10.1080/15360288.2019.1690616
MLA
Henson, Brianna, et al. "Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.." Journal of pain & palliative care pharmacotherapy, 2020. https://doi.org/10.1080/15360288.2019.1690616
RethinkPeptides
RethinkPeptides Research Database. "Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their..." RPEP-04850. Retrieved from https://rethinkpeptides.com/research/henson-2020-calcitonin-generelated-peptide-cgrp
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.